SCHEDULE: T. Rowe Price Boosts Kymera Therapeutics Stake to 7.1%
Beneficial Ownership Report
T. Rowe Price Associates, Inc. has reported an increased beneficial ownership of 7.1% in Kymera Therapeutics Inc. common stock.
Summary
- T. Rowe Price Associates, Inc. reported beneficial ownership of 5,097,704 shares of Kymera Therapeutics Inc. common stock.
- This ownership represents 7.1% of the total class of securities.
- T. Rowe Price holds sole voting power over 4,973,066 shares and sole dispositive power over 5,097,378 shares.
- This filing is an Amendment No. 6 to a Schedule 13G, indicating a change from a previous filing.
- T. Rowe Price Associates, Inc. is classified as an investment adviser.
Sentiment
Score: 6
Explanation: The filing indicates a significant institutional stake, which is generally viewed positively as a vote of confidence, but it does not contain operational or financial performance details to warrant a higher score.
Positives
- A significant institutional investor, T. Rowe Price Associates, Inc., holds a substantial 7.1% stake in Kymera Therapeutics Inc., which can be interpreted as a vote of confidence in the company.
Negatives
- No negative information is disclosed in this beneficial ownership report.
Risks
- This filing does not contain information regarding specific risks related to Kymera Therapeutics Inc.'s operations or financial health.
Future Outlook
This filing does not provide any forward-looking statements or guidance regarding Kymera Therapeutics Inc.'s future outlook.
Industry Context
This beneficial ownership report does not provide information to analyze how this ownership stake relates to broader industry trends or competitors.
Stakeholder Impact
- Shareholders may view the significant institutional ownership by T. Rowe Price Associates, Inc. as a positive signal of confidence in Kymera Therapeutics Inc.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which requires the filing of this statement. |
| 11/14/2025 | Date of signature for the filing by T. Rowe Price Associates, Inc. |
Keywords
Kymera Therapeutics, T. Rowe Price, Institutional Ownership, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.